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Abstract
Background: Hirschsprung disease (HSCR) is a neurocristopathy characterized by the absence of parasympathetic
intrinsic ganglion cells in the submucosal and myenteric plexuses along a variable portion of the intestinal tract. In
approximately 18% of the cases HSCR also presents with multiple congenital anomalies including recognized
syndromes.
Methods: A combination of MLPA and microarray data analysis have been undertaken to refine a duplication at
the Xq28 region.
Results: In this study we present a new clinical association of severe neonatal encephalopathy (Lubs syndrome)
and HSCR, in a male patient carrying a duplication at the Xq28 region which encompasses the MECP2 and L1CAM
genes.
Conclusions: While the encephalopathy has been traditionally attributed to the MECP2 gene duplication in
patients with Lubs syndrome, here we propose that the enteric phenotype in our patient might be due to the
dosage variation of the L1CAM protein, together with additional molecular events not identified yet. This would be
in agreement with the hypothesis previously forwarded that mutations in L1CAM may be involved in HSCR
development in association with a predisposing genetic background.
Background
Hirschsprung disease (HSCR, OMIM 142623) is a con-
genital malformation of the hindgut characterised by the
absence of parasympathetic intrinsic ganglion cells in
the submucosal and myenteric plexuses. It is regarded
as the consequence of the premature arrest of the cra-
niocaudal migration of vagal neural crest cells in the
hindgut between the fifth and 12th week of gestation to
form the enteric nervous system (ENS) and is therefore
regarded as a neurocristopathy [1]. HSCR occurs as an
isolated trait in 70% of cases. Genetic mapping in
families and mutational screening of candidate genes,
together with the study of several natural and knockout
animal models, clearly have shown the involvement of
multiple genes in the pathogenesis of HSCR [1,2]. Of
them, RET proto-oncogene is the major gene involved
in the disease, with classical coding hypomorphic muta-
tions accounting for 50% of familial cases and 7-35% of
sporadic patients [2], and a common variant within a
transcriptional enhancer of its intron 1 which seems to
have a prominent role for a great proportion of sporadic
cases [3].
On the other hand, a chromosomal abnormality is
associated in 12% of HSCR cases, trisomy 21 being by
far the most frequent (> 90%). Associated congenital
anomalies are found in 18% of the HSCR patients.
Among those HSCR-associated syndromes, there exist
some clinical presentations with central nervous system
anomalies, including the HSAS/MASA spectrum
(OMIM 307000 and 303350) ascribed to mutations in
the X-linked L1CAM gene [1,4]. Indeed, until now
mutations of the L1CAM gene (OMIM 308840) have
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been found in nine out of ten patients reported to show
association of X-linked hydrocephalus with HSCR
[4-10]. In addition, two cases with both acrocallosal syn-
drome and HSCR have been also linked to L1CAM
mutations [11]. Therefore, although the question of
L1CAM being a modifier gene in HSCR has been raised
with no definitive answer given thus far [7,8], the whole
data suggest that mutations in L1CAM may be involved
in HSCR development in association with a predisposing
background [9].
In this report we present a clinical case of neonatal
severe encephalopathy (OMIM 300673) associated with
HSCR, presenting with a duplication in the X chromo-
some encompassing the MECP2 (OMIM 300005) and
L1CAM genes among others. To our knowledge this is
the first time in which this kind of association has been
described and an extensive analysis has been performed
in order to completely dissect its molecular cause.
Methods
Patients
The affected patient was the second child born to a
healthy couple. He was born at full term with a birth
weight of 3.500 Kg. He was hypotonic and failed to
thrive in the neonatal period. The patient presented
with severe constipation, a distended abdomen, and
intestinal biopsy confirmed Hirschsprung disease with
aganglionosis extending up to the sigmoid. During his
first years of life he developed tonic-clonic seizures and
frequent respiratory tract infections. MRI scan showed a
discrete increase of the subarachnoid space and dilata-
tion of the ventricular system, cavum septum pelluci-
dum and cavum vergae. He was clinically diagnosed
with neonatal encephalopathy, benign external hydroce-
phalus and sideropenia. The child is currently 13 years
old and has not developed speech nor walked, although
he can sit without support. He is dysmorphic with a
long thin face, down slanting palpebral fissures, diver-
gent strabismus, prognatism, marked ojival palate, long
fingers and bilateral cryptorchid. He also presents bilat-
eral hip dislocation. Molecular testing for Angelman and
Rett syndrome was negative, and karyotype was normal.
As shown in the family tree (Figure 1), our index
patient had a cousin who shared some of his clinical
signs and died at the age of 1, fifteen years ago. Clinical
reports for this patient describe a congenital midline
malformation, with unspecified ventricular alterations
and partial agenesis of the corpus callosum. Unfortu-
nately no additional clinical information is available for
this patient.
We had also available the DNA from the mother,
sister, three maternal aunts and two maternal cousins of
our index patient (individuals II.1, II.3, II.5, II.6, III.2,
III.4 and III.6 of the family tree). An informed consent
was obtained from all the participants for clinical and
molecular genetic studies. The study conformed to the
tenets of the declaration of Helsinki and was approved
by the “Committee of Ethics and Clinical Investigation”
from Hospitales Universitarios Virgen del Rocío.
MLPA analysis
The MLPA (Multiple Ligation Probe-dependent Ampli-
fication) method employed was as described by
Schouten et al. [12], using MLPA kits purchased from
MRC-Holland (Amsterdam, The Netherlands), and
according to manufacturer’s recommendations. MLPA is
a variation of the PCR that permits multiple targets to
be amplified with only a single primer pair. Each probe
consists of a two oligonucleotides which recognise adja-
cent target sites on the DNA. One probe oligonucleotide
contains the sequence recognized by the forward primer,
the other the sequence recognised by the reverse primer.
Figure 1 Pedigree of the patient carrying the duplication at Xq28. Together with the index patient (III.7), individuals II.1, II.5, II.6 and III.2
were found to be healthy carriers of the rearrangement, while II.3, III.4 and III.6 resulted negative for the testing.
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Only when both probe oligonucleotides are hybridized
to their respective targets, can they be ligated into a
complete probe. Each complete probe has a unique
length, so that its resulting amplicons can be separated
and identified by capillary electrophoresis. Since the for-
ward primer used for probe amplification is fluores-
cently labeled, each amplicon generates a fluorescent
peak which can be detected by a capillary sequencer.
Comparing the peak pattern obtained on a given sample
with that obtained on various reference samples, the
relative quantity of each amplicon can be determined.
Initial MLPA studies were aimed to completely rule out
the possibility of any microdeletion syndrome included
in the P245 kit. When a duplication was observed for
the three probes binding the MECP2 gene, MLPA was
performed using the P015D kit, which included probes
for the four exons of this gene, together with IRAK1,
L1CAM, IDH3G and SLC6A8, alongside 12 X chromo-
some and four autosomal control probes. The P106 kit
for X-linked mental retardation syndromes, comprising
3 genes at Xq28 (GDI1, AFF2, SLC6A8) and several
other genes along the whole X chromosome was also
employed to analyze the extent of the duplication. Sub-
sequently and in order to verify the results, we used the
P049 kit which covered a series of genes at Xq.28 as
FMR2, IDS, PNCK, SLC6A8, BCAP31, ABCD1, IDH3G,
L1CAM, IRAK1, MECP2, FLNA, GDI1, FVIII and
SYBL1, and also included six chromosome X control
probes. Fragment analyses were performed using the
3730 DNA analyzer (Applied Biosystems, Foster City,
CA, USA) and for data analysis we used GeneMarker v
1.6 (Softgenetics L.L.C). We normalized the samples by
the peak height, and included control individuals who
had previously been confirmed to have no CNVs of the
studied genes. Furthermore, the assays were performed
in duplicated to confirm the robustness of the analysis.
Microarray analysis
DNA samples from our patient and his mother were
hybridized with Genome wide human SNP 6.0 arrays
(Affymetrix), in order to analyze the presence CNVs.
Samples (20 μl) diluted to 50 ng/μl were processed in
the GeneChip® Instrument System platform (Affymetrix
UK L) following the manufacturer’s recommendations.
Copy number data were generated by comparing inten-
sities for both SNP and copy number probes “in silico”
to the HapMap control provided by Affymetrix. The
resulting log2ratios were then analysed using a Hidden
Markov Model (HMM) to generate copy number calls
for each probe. The quality of the log2 data was
assessed by the degree of variation, determined by the
MAPD metric. MAPD is defined as the Median of the
Absolute value of all Pairwise Differences between log2
ratios for a given chip. High MAPD > 0.4 (using the
HapMap control) is considered to be the cut-off at
which copy numbers can no longer be accurately called.
X inactivation analysis
X inactivation assays performed for the female subjects
of the family as well as for controls, consisted in the
examination of the human androgen-receptor gene
(HUMARA, Xq11.2) methylation status, as described by
Allen et al. [13]. This study was pertinent to explain the
complete absence of any clinical manifestation in all the
female carriers of the rearrangement within this family.
Samples were separated on an ABI3730 automated
DNA sequencer (Applied Biosystems) and were analyzed
with GeneMapper software for peak positions and area
intensity calculations. These data were further processed
with the use of Excel.
Mutational screening, SNPs genotyping and haplotyping
PCR - dHPLC analysis was undertaken for the muta-
tional screening of RET and other HSCR related genes
such as EDNRB, EDN3, SOX10, PHOX2B, GDNF and
NTN, using previously described conditions [14,15]. The
whole coding sequence of the L1CAM gene was also
screened in both the affected child and his mother by
direct sequencing (conditions available on request).
RET SNPs c.73-126G > T (rs2565206), c.73-1370C > T
(rs2505532), c.73-1463T > C (rs2505533) and c.73+
9277T > C (rs2435357) were genotyped in our patient
employing Taqman based techniques for allelic discrimi-
nation (TaqMan® SNP Genotyping Assay, Applied Bio-
systems, Foster City, CA) as previously described [16].
Results
Investigation of the affected patient using the different
MLPA kits demonstrated a duplication at Xq28 includ-
ing MECP2, IRAK1, L1CAM, IDH3G and a region of
ABCD1 from exon 3 upstream. Normal dosages were
observed for exons 1 and 2 of ABCD1 as well as for the
remaining neighbouring genes GDI1, SLC6A8, BCAP31
or PNCK. Taking into account the relative positions of
all these genes, the duplication seemed to comprise
approximately a region of a minimum of 297 Kb. Subse-
quently, by performing copy number analysis using the
Affymetrix 6.0 SNP chip, we were able to confirm the
presence of the rearrangement and characterized it in
detail (Figure 2). As shown in figure 3, a duplication
encompassing 621 Kb and containing two stretches of
65,8 Kb and 35.1 Kb of non-duplicated sequences, was
detected in our index patient.
Segregation analysis of the family by MLPA showed that
the duplication was not a de novo event but had been
inherited from his mother, and also was carried by other
four healthy females within the family, including the
mother of the deceased cousin (Figure 1). X inactivation
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testing on the DNA samples for all the asymptomatic
female carriers, showed a marked skewed inactivation
with the inactive X chromosome being the duplicated
one (99,999975% of active normal allele versus
0,000025% of active mutant allele), which would clearly
explain the absence of any clinical feature in those
individuals.
On the other hand, the mutational screening of the
coding regions of RET and the remaining genes tested
including L1CAM, revealed no mutations which could
be attributable to HSCR phenotype in our patient.
Moreover molecular testing of the RET haplotype com-
prising specific variants within its intron 1, showed
that this patient did not carry the “HSCR-associated
combination” [17,18], nor the so-called “enhancer
mutation” [3].
Discussion
Over 50 patients have to date been reported with Xq28
duplications varying in size from 0.2 Mb to larger scale
Figure 2 Representation of the duplicated region in our patient refined with the Genome wide human SNP 6.0 arrays (Affymetrix).
Figure 3 Schematic representation of the genomic region at Xq28 involved in the duplication in our patient. The regions covered by
each of the MLPA sets of probes (P245, P015 and P049) are indicated. The refinement of the region using the Genome wide human SNP 6.0
array of Affymetrix is also shown.
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duplications extending beyond Xq27. Most have
included the MECP2 and L1CAM genes, although none
of them have been reported to present with Hirsch-
sprung disease [19-21]. It has been suggested that the
clinical features associated to neonatal encephalopathy
in males carrying the Xq28 duplication might be solely
due to the MECP2 gene, as patients with duplications
involving this region alone have been reported with
the same classical phenotype [19,21]. Indeed, an OMIM
number is used to specifically design the disorder
caused by duplication or triplication of MECP2
(OMIM#300260; Lubs X-Linked mental retardation syn-
drome). Although spasticity, severe learning disability,
axial hypotonia and frequent chest infections have been
common findings within this group of patients, gastroin-
testinal symptoms have been much rarer. Only worth of
note, in the report by Clayton-Smith et al., eight families
with several male affected patients carrying Xq28 dupli-
cations had presented with intestinal pseudo-obstruction
or bladder distension, but these features were attributed
exclusively to the duplication of the FLNA gene [21].
Several arguments supported such assumption, since
these authors had also found 2 other families carrying
intragenic duplications of FLNA and presenting exclu-
sively the enteric phenotype. Moreover, Gargiulo et al.
had already reported point FLNA mutations in X-linked
families with pseudo-obstruction [22]. The pathogenic
mechanism proposed by the authors to explain how
both duplications and truncating mutations of the FLNA
gene could lead to intestinal pseudo-obstruction, was
the hypothesis that the amount of FLNA would be criti-
cal for neuronal migration, and either its increased or
decreased expression could interfere with the normal
migration process [21]. In our particular case we could
propose exactly the same pathogenic mechanism for the
connection between the L1CAM gene and Hirschsprung
disease in our patient carrying the duplication at Xq28.
The L1 cell adhesion molecule is a membrane glycopro-
tein belonging to a large class of immunoglobulin super-
family cell adhesion molecules (CAMs) that mediate
cell-to-cell adhesion at the cell surface. The L1CAM
protein is found primarily in the nervous system and is
important in neuronal adhesion, migration, neurite out-
growth, and myelination [4]. Mutations in the L1CAM
gene cause neurological abnormalities of variable sever-
ity, including congenital hydrocephalus, agenesis of the
corpus callosum, spastic paraplegia, bilaterally adducted
thumbs, aphasia, and mental retardation (see OMIM).
Interestingly, L1CAM is the only gene included in the
duplicated region which has been verified to be a ENS-
expressed gene and to play a key role in its development
during embryogenesis [23], and some cases of patients
with either X-linked hydrocephalus or acrocallosal syn-
drome and HSCR have been reported to present
L1CAM mutations (visit HGMD http://www.hgmd.cf.ac.
uk/ac/all.php). In contrast, none of the remaining genes
encompassed by the rearrangement, such as IRAK1 or
IDH3G have been previously related to HSCR. All the
L1CAM mutational events reported so far to be respon-
sible for the manifestation of the corresponding clinical
pictures, are point sequence changes [4,6,8,10,11] or
small deletions [5,9], whose proposed pathogenic
mechanisms lead to the suspicion that decreased
L1CAM may be a modifying factor in the development
of HSCR [4]. It would be licit to speculate that also an
increase in the amount of L1CAM, due to a duplication
in the dosage of this gene, might be involved someway
in the pathogenesis of Hirschsprung in this particular
patient. In other words it would be plausible that the
amount of L1CAM would be critical during ENS devel-
opment, and either an increase or decrease of this pro-
tein could interfere with the processes of neuronal
adhesion and migration.
The association between encephalopathy and HSCR
should not be considered surprising as brain develop-
ment is largely controlled by the same neural growth
factors acting in the ENS [24]. Because the frequency of
Lubs X-linked mental retardation syndrome is estimated
to be extremely low (only around 50 cases being
reported to date), and the frequency of HSCR is
approximately 1:5000, then the anticipated incidence of
both together would be almost inexistent by chance
alone. So it is not probable that the association of both
clinical phenotypes has occurred accidentally and by dif-
ferent molecular events. This statement is supported by
the fact that L1CAM abnormality has been previously
proposed to contribute to HSCR onset [8,9,25]. Parisi
et al. hypothesized that in those cases in which X-linked
hydrocephalus presents together with HSCR, either RET
or another HSCR gene contributes to aganglionosis
under the influence of a defective L1CAM gene, and
L1CAM may act as an X linked modifier gene for the
development of HSCR [8]. We therefore propose a simi-
lar role for L1CAM in the context of the association of
Lubs syndrome and HSCR. Given the complex nature
of HSCR, it would be conceivable that the duplication
at Xq28 region including the L1CAM gene, together
with another still unidentified molecular events, could
lead to the manifestation of the disease in our patient.
The existence of those additional molecular events
would also explain why no other patients carrying
MECP2-L1CAM duplications reported to date present
with HSCR [19-21]. In addition, we have also to argue
that children with congenital severe neonatal encephalo-
pathy cannot communicate symptoms such as constipa-
tion, and originally, they have a constipation tendency;
so there may be several cases of HSCR among those
patients that goes undiagnosed because of a premature
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death, just as it occurred with the cousin of our index
patient.
Conclusions
Although a more comprehensive analysis of additional
HSCR genes is warranted, our results support an invol-
vement of L1CAM duplication in the pathogenesis of
HSCR, and present evidence of a possible novel syndro-
mic form of Hirschsprung disease.
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